BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 24941916)

  • 1. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
    Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
    Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis.
    Ljung L; Rantapää-Dahlqvist S; Jacobsson LT; Askling J
    Ann Rheum Dis; 2016 Dec; 75(12):2087-2094. PubMed ID: 26984007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
    Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
    BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.
    Wadström H; Frisell T; Sparén P; Askling J;
    Ann Rheum Dis; 2016 Jul; 75(7):1272-8. PubMed ID: 26755797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.
    Raaschou P; Frisell T; Askling J;
    Ann Rheum Dis; 2015 Dec; 74(12):2137-43. PubMed ID: 25107559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK; Galloway JB; Lunt M; Davies R; Low AL; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL
    Ann Rheum Dis; 2017 Mar; 76(3):497-503. PubMed ID: 27502891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
    Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
    Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.
    Low AS; Symmons DP; Lunt M; Mercer LK; Gale CP; Watson KD; Dixon WG; Hyrich KL;
    Ann Rheum Dis; 2017 Apr; 76(4):654-660. PubMed ID: 28073800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.
    Barbulescu A; Delcoigne B; Askling J; Frisell T
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
    Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK; Lunt M; Low AL; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2015 Jun; 74(6):1087-93. PubMed ID: 24685910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
    Mercer LK; Askling J; Raaschou P; Dixon WG; Dreyer L; Hetland ML; Strangfeld A; Zink A; Mariette X; Finckh A; Canhao H; Iannone F; Zavada J; Morel J; Gottenberg JE; Hyrich KL; Listing J
    Ann Rheum Dis; 2017 Feb; 76(2):386-391. PubMed ID: 27307502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis.
    Low AS; Lunt M; Mercer LK; Watson KD; Dixon WG; Symmons DP; Hyrich KL
    Arthritis Rheumatol; 2016 Jun; 68(6):1337-45. PubMed ID: 26749043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
    Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
    Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
    Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
    Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
    PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
    Xie F; Yun H; Bernatsky S; Curtis JR
    Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.